A non-opioid pain startup believes it can top the bupivacaine market — and it's thinking in terms of weeks, not days

Kyle Blankenship

The road to non-opioid pain management has swallowed biotech players for years as drug developers have smacked their heads against safety flags. A California biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A non-opioid pain startup believes it can top the bupivacaine market — and it's thinking in terms of weeks, not days

Kyle Blankenship

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

A non-opi­oid pain start­up be­lieves it can top the bupi­va­caine mar­ket — and it's think­ing in terms of weeks, not days

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

A non-opioid pain startup believes it can top the bupivacaine market — and it's thinking in terms of weeks, not days